Isodiol International to Present at New West Summi

VANCOUVER, British Columbia, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”) , a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today Marvin Washington, former NFL athlete and brand ambassador for Isodiol, will be speaking at the New West Summit Cannabis Conference being held at the Marriot City Center in Oakland, October 13-15, 2017. The Company will also be exhibiting its hemp-derived CBD products throughout the conference.

Isodiol International CEO, Marcos Agramont stated, “The CBD market is projected to grow to $2.1 billion by 2020, with hemp-derived CBD accounting for $450 million. We have been able to position ourselves as leaders in the development of hemp-based CBD products by making significant investments in innovative delivery methods. I look forward to sharing our experience with conference attendees, as well as engaging with veritable industry leaders on developments within the cannabis space.”

Mr. Washington will take the stage as a panelist to discuss the anti-inflammatory and pain-relieving properties of CBD for athletes. NFL veterans Reggie Williams and Eben Britton, and Hall of Fame NBA player Rick Barry, will join Mr. Washington in an open discussion on CBD as an effective alternative to the harmful prescription opioids they receive while in the league.

For more information on Isodiol, please visit www.isodiol.com  

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook : https://www.facebook.com/isodiol/ Twitter: @isodiol

ON BEHALF OF THE BOARD Marcos Agramont , CEO & Director

INVESTOR RELATIONS: Ir@isodiol.com www.isodiol.com

MEDIA CONTACT: Carrie Booze North 6th Agency 212-334-9753 ext.142 Isodiol@n6a.com

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.